PMID- 35057594
OWN - NLM
STAT- MEDLINE
DCOM- 20220124
LR  - 20220124
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 69
IP  - 12
DP  - 2022 Dec
TI  - Efficacy and Safety of Empagliflozin as Add on in Patients with Type II Diabetes 
      Mellitus (DM) Inadequately Controlled on Triple Drug Combination.
PG  - 11-12
AB  - OBJECTIVES: Diabetes mellitus (DM) refers to a group of metabolic disorders 
      characterized by hyperglycemia resulting from insulin resistance, insulin action 
      or both. Despite availability of various treatment modalities it is difficult to 
      achieve the desired glycemic control in many patients. In such patients new class 
      of anti-diabetic agent sodium-glucose co-transporter II (SGLT2) inhibitors has 
      been approved by FDA. SGLT-2 inhibitor Empagliflozin has been associated with 
      HbA1c reduction and weight loss in a broad range of patients with type 2 Diabetes 
      Mellitus (T2DM). METHODS: An open label, interventional, single arm, 24 weeks 
      study was done on 120 patients who were inadequately controlled on three oral 
      hypoglycaemic agents and reluctant to take insulin therapy. Empagliflozin 25 mg 
      once a day was added to ongoing triple drug therapy. Changes in glycemic 
      parameters like fasting blood sugar levels, post-prandial blood sugar levels, 
      HbA1C, body weight, systolic and diastolic blood pressure and safety profile were 
      assessed at baseline, three months and sixth months. Study was conducted at MGM 
      medical college and hospital, Aurangabad in collaboration with Department of 
      Medicine. RESULTS: Our study revealed Empagliflozin 25 mg once daily when used as 
      add on to ongoing triple drug therapy has shown 3.02 % reduction in HbA1c and 
      3.83 kg reduction in bodyweight. CONCLUSION: Empagliflozin a SGLT 2 inhibitor is 
      a promising drug for reduction in HbA1c value and body weight in patients with 
      T2DM who are inadequately controlled on triple drug therapy and are reluctant to 
      insulin therapy.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Bhosle, Deepak
AU  - Bhosle D
AD  - Consultant Diabetologist, Deogiri Diabetes Care Center, Professor and HOD, MGM 
      Medical College, Aurangabad, Maharashtra.
FAU - Chavan, Snehal
AU  - Chavan S
AD  - Tutor, MGM Medical College, Aurangabad, Maharashtra.
FAU - Kardile, Shraddha
AU  - Kardile S
AD  - Asst. Professor, Department of Pharmacology, MGM Medical College, Aurangabad, 
      Maharashtra.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucosides)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/adverse effects
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Combinations
MH  - Glucosides/adverse effects
MH  - Humans
EDAT- 2022/01/22 06:00
MHDA- 2022/01/27 06:00
CRDT- 2022/01/21 04:43
PHST- 2022/01/21 04:43 [entrez]
PHST- 2022/01/22 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2022 Dec;69(12):11-12.